About us

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Antwerp
Type
Privately Held
Founded
2017

Locations

Employees at Agomab

Updates

Similar pages